Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL or Richter's Syndrome

Jennifer L. Crombie, MD, Svitlana Tyekucheva, PhD, Zixu Wang, MS, Alexandra Savell, BS, Lisa Brennan, RN, BSN, Jessica Lowney, Karen Francoeur, RN, Josie Montegaard, NP, Austin I. Kim, MD, Jacob D. Soumerai, MD, Jon E. Arnason, MD, Allan Louie Cruz, MD, Sigrid Berg, MD, David C. Fisher, MD, Jennifer R Brown, MD PhD, Matthew S. Davids, MD

Blood (2020) 136 (Supplement 1): 46–47.

https://doi.org/10.1182/blood-2020-138811

Published: 2020

Journal Articles

A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL

Jennifer L. Crombie, MD, Svitlana Tyekucheva, PhD, Alexandra Savell, BS, Karen Francoeur, RN, Mark Choiniere, BA, Josie Montegaard, NP, Jacob D. Soumerai, MD, Jon E. Arnason, MD, David C. Fisher, MD, Jennifer R. Brown, MD PhD, Matthew S. Davids, MD

Blood (2019) 134 (Supplement_1): 1763.

https://doi.org/10.1182/blood-2019-127343

Published: 2019

Journal Articles

Initial Results of a Phase Ib Study of Ibrutinib in Combination with Obinutuzumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Matthew S. Davids, MD, Haesook T Kim, PhD, Alexandra Savell, BS, Carlos Santiago-Medero, Karen Francoeur, RN, Jeremy S. Abramson, MD MMSc, Eric D. Jacobsen, MD, Ann S LaCasce, MD MSc, David C. Fisher, MD PhD, Jennifer R. Brown, MD PhD

Blood (2017) 130 (Supplement 1): 4317.

https://doi.org/10.1182/blood.V130.Suppl_1.4317.4317

Published: 2017

Journal Articles

A Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients

Matthew S. Davids, MD, Haesook T Kim, PhD, Danielle M. Brander, MD, Jad Bsat, BA, Alexandra Savell, BS, Karen Francoeur, RN, Caron Jacobson, MD, Samuel Y. Ng, MDPhD, Ann S LaCasce, MD MSc, Ephraim P. Hochberg, MD, Ronald W. Takvorian, MD, Jeremy S. Abramson, MD MMSc, David C. Fisher, MD PhD, Jennifer R. Brown, MD PhD

Blood (2017) 130 (Supplement 1): 496.

https://doi.org/10.1182/blood.V130.Suppl_1.496.496

Published: 2017

Journal Articles

Initial Results of a Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients

Matthew S. Davids, Haesook T. Kim, PhD, Danielle M. Brander, MD, Jad Bsat, BA, Alexandra Savell, BS, Karen Francoeur, RN, Jeffrey Hellman, PA-C, Caron A. Jacobson, MD, Ephraim Hochberg, MD, Ronald Takvorian, MD, Jeremy S. Abramson, MD, David C. Fisher, MD, Jennifer R. Brown, MD PhD

Blood (2016) 128 (22): 3243.

https://doi.org/10.1182/blood.V128.22.3243.3243

Published: 2016

Journal Articles

TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study

Matthew S. Davids, Haesook T. Kim, PhD, Alyssa Nicotra, BA, Alexandra Savell, BS, Karen Francoeur, RN, Jeffrey Hellman, PA-C, Hari P. Miskin, MS, Peter Sportelli, Asad Bashey, MD PhD, Laura Stampleman, MD, Jens Rueter, MD, Adam Boruchov, MD, Jon Arnason, MD, Caron A. Jacobson, MD, David C. Fisher, MD, Jennifer R. Brown

Blood (2016) 128 (22): 641.

https://doi.org/10.1182/blood.V128.22.641.641

Published: 2016

Journal Articles

Preliminary Results of a Phase Ib Study of Duvelisib in Combination with FCR (dFCR) in Previously Untreated, Younger Patients with CLL

Matthew S. Davids, MD, Haesook T. Kim, PhD, Elizabeth Gilbert, Leslie Cowen, Karen Francoeur, RN, Jeffrey Hellman, PA-C, Jon E. Arnason, MD, David C. Fisher, MD, Jennifer R. Brown, MD PhD

Blood (2015) 126 (23): 4158.

https://doi.org/10.1182/blood.V126.23.4158.4158

Published: 2015

Journal Articles

A Phase II Study of Ofatumumab-High Dose Methylprednisolone Followed By Ofatumumab-Alemtuzumab in 17p Deleted or TP53 Mutated CLL

Matthew S. Davids, MD, Haesook T. Kim, PhD, Stacey M. Fernandes, Jeffrey Hellman, PA-C, Karen Francoeur, RN, Jon E. Arnason, MD, Eric Jacobsen, MD, Ann S LaCasce, MD, David C. Fisher, MD, Jennifer R. Brown, MD PhD

Blood (2015) 126 (23): 4159.

https://doi.org/10.1182/blood.V126.23.4159.4159

Published: 2015

NARROW

Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL or Richter's Syndrome

A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLL

Initial Results of a Phase Ib Study of Ibrutinib in Combination with Obinutuzumab in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

A Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients

Initial Results of a Multicenter, Phase II Study of Ibrutinib Plus FCR (iFCR) As Frontline Therapy for Younger CLL Patients

TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study

Preliminary Results of a Phase Ib Study of Duvelisib in Combination with FCR (dFCR) in Previously Untreated, Younger Patients with CLL

A Phase II Study of Ofatumumab-High Dose Methylprednisolone Followed By Ofatumumab-Alemtuzumab in 17p Deleted or TP53 Mutated CLL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only